BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yeung RH, Chapman TR, Bowen SR, Apisarnthanarax S. Proton beam therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2017;17:911-924. [PMID: 28825506 DOI: 10.1080/14737140.2017.1368392] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Cozzi L, Comito T, Fogliata A, Franzese C, Tomatis S, Scorsetti M. Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma. PLoS One 2018;13:e0201992. [PMID: 30102749 DOI: 10.1371/journal.pone.0201992] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
2 Iizumi T, Okumura T, Sekino Y, Takahashi H, Tsai YL, Takizawa D, Ishida T, Hiroshima Y, Nakamura M, Shimizu S, Saito T, Numajiri H, Mizumoto M, Nakai K, Sakurai H. Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma. J Radiat Res 2021;62:682-7. [PMID: 34036362 DOI: 10.1093/jrr/rrab040] [Reference Citation Analysis]
3 Cozzi L, Comito T, Loi M, Fogliata A, Franzese C, Franceschini D, Clerici E, Reggiori G, Tomatis S, Scorsetti M. The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation. Technol Cancer Res Treat 2020;19:1533033820980412. [PMID: 33287650 DOI: 10.1177/1533033820980412] [Reference Citation Analysis]
4 Yoo GS, Yu JI, Park HC. Current role of proton beam therapy in patients with hepatocellular carcinoma. Int J Gastrointest Interv 2021;10:175-82. [DOI: 10.18528/ijgii210043] [Reference Citation Analysis]
5 Chun S, Nam K, Lee K. Proton Beam Induces P53-mediated Cell Cycle Arrest in HepG2 Hepatocellular Carcinoma Cells. Biotechnol Bioproc E 2020;25:141-8. [DOI: 10.1007/s12257-019-0390-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Brasse D, Burckel H, Marchand P, Rousseau M, Ouadi A, Vanstalle M, Finck C, Laquerriere P, Boisson F. Comparison of the [18F]-FDG and [18F]-FLT PET Tracers in the Evaluation of the Preclinical Proton Therapy Response in Hepatocellular Carcinoma. Mol Imaging Biol 2021;23:724-32. [PMID: 33847900 DOI: 10.1007/s11307-021-01602-3] [Reference Citation Analysis]
7 Sayan M, Yegya-Raman N, Greco SH, Gui B, Zhang A, Chundury A, Grandhi MS, Hochster HS, Kennedy TJ, Langan RC, Malhotra U, Rustgi VK, Shah MM, Spencer KR, Carpizo DR, Nosher JL, Jabbour SK. Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes. Front Oncol 2019;9:345. [PMID: 31275846 DOI: 10.3389/fonc.2019.00345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
8 Yoo GS, Yu JI, Park HC. Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives. World J Gastroenterol 2018; 24(28): 3090-3100 [PMID: 30065555 DOI: 10.3748/wjg.v24.i28.3090] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
9 Wang L, Wang W, Rong W, Li Z, Wu F, Liu Y, Zheng Y, Zhang K, Siqin T, Liu M, Chen B, Wu J. Postoperative adjuvant treatment strategy for hepatocellular carcinoma with microvascular invasion: a non-randomized interventional clinical study. BMC Cancer 2020;20:614. [PMID: 32611327 DOI: 10.1186/s12885-020-07087-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Sun X, Qian Y, Wang X, Cao R, Zhang J, Chen W, Fang M. LncRNA TRG-AS1 stimulates hepatocellular carcinoma progression by sponging miR-4500 to modulate BACH1. Cancer Cell Int 2020;20:367. [PMID: 32774161 DOI: 10.1186/s12935-020-01440-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
11 Takahashi H, Sekino Y, Mori K, Okumura T, Nasu K, Fukuda K, Masuoka S, Iizumi T, Hasegawa N, Sakurai H, Minami M. Indicator for local recurrence of hepatocellular carcinoma after proton beam therapy: analysis of attenuation difference between the irradiated tumor and liver parenchyma on contrast enhancement CT. Br J Radiol 2020;93:20190375. [PMID: 31670572 DOI: 10.1259/bjr.20190375] [Reference Citation Analysis]
12 Labadie KP, Schaub SK, Khorsand D, Johnson G, Apisarnthanarax S, Park JO. Multidisciplinary approach for multifocal, bilobar hepatocellular carcinoma: A case report and literature review. World J Hepatol 2019; 11(1): 119-126 [PMID: 30705724 DOI: 10.4254/wjh.v11.i1.119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]